The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.
The long-acting therapy, also known as nirsevimab, was given EU marketing authorisation for the prevention of disease from infections caused by the respiratory syncytial virus (RSV), Sanofi said in a statement.
In the United States, the product, in which Swedish Orphan Biovitrum also holds some rights, is still under regulatory review as a potential breakthrough therapy.
Beyfortus, given by intramuscular injection, was recommended for approval by the European Medicines Agency in September.
https://finance.yahoo.com/news/sanofi-astra-win-eu-approval-070000794.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.